Kornimate/medical-research-clean huggingface dataset:
characterization of hepatopathy in turner syndrome: analysis of determinants

Conditions: Turner Syndrome

Summary: the present study is therefore aimed at investigating the prevalence of hepatic alterations (laboratory and imaging) in adult patients with ts and generating hypothesissto the possible etiopathogenetic factors most involved, as well as evaluating the correlation between biochemical and structural abnormalities. thus, the study could provide relevant etiopathogenetic and prognostic results on the development of hepatopathy in ts patients.

the study is an observational retrospective cohort type; patients with ts in longitudinal monitoring at the u.o.c. of endocrinology and diabetes prevention and care, dimec, of irccs policlinico s. orsola of bologna will be enrolled. the diagnosis of ts was made for most patients by the pediatrics unit of policlinico s. orsola; in rare cases it was performed in adulthood by our operating unit or at another center; in all cases, the diagnosis was made by karyotype analysis on peripheral blood. the patients, as per clinical practice, underwent clinical evaluation with measurement of anthropometric parameters; an evaluation of the patients' medical history will be performed, paying attention to possible diagnosis of metabolic comorbidities and autoimmune diseases. complete information regarding the history of menstrual cycles and replacement therapies used will also be collected. finally, laboratory investigations are planned.

Eligibility criteria:
inclusion criteria: * diagnosis of turner syndrome made by karyotype analysis on peripheral blood. * age 18 years or older * written informed consent obtained exclusion criteria: * ts patients on therapy with drugs responsible for significant liver enzyme alterations (liver function alteration, lfa).
side effect profiles of brand name versus generic oral contraceptives

Conditions: Contraception

Summary: this is a randomized control trial of ortho tricyclen versus trinessa (generic equivalent) to determine if they have similar effects. women will be randomized to receive either ortho tricyclen or trinessa oral contraceptives and will be asked to keep a daily dairy of any symptoms or bleeding experienced. once a month, participants will be asked to complete a survey. the objective is to compare generic oral contraceptives (ocps) and brand name ocps with respect to side effect profiles including bleeding patterns, mood changes, nausea and vomiting, frequency of menstrual cramps, breast tenderness, elevation in blood pressure, stroke, blood clots and patient compliance.

this is a double blind randomized controlled trial of ortho tricyclen™ vs. trinessa™ (generic equivalent) to determine if they have similar effects on bleeding patterns, namely days of menstrual flow, amount of bleeding, and intermenstrual bleeding. women will score these parameters using a survey with objective measures for days of bleeding, amount of flow, and days of breakthrough bleeding. as secondary outcomes, we will compare the side effect profiles of each in regards to nausea, vomiting, breast tenderness, menstrual cramps, mood changes, and thromboembolic events. patients will record in their daily diary if one of the outcomes occurs or not. we will observe whether the events occur and the number of occurrences within the six month time period.

Eligibility criteria:
inclusion criteria: * nonsmoker * not pregnant * not planning to become pregnant in the next 6 months * not taking hormonal birth control for at least 3 months previous to entering the study * no history of fibroids * no history of ovarian cysts * no history of dysfunctional uterine bleeding exclusion criteria: * pregnant * under the age of 18 * over the age of 35 * history of irregular uterine bleeding * history of ovarian cysts * history of fibroids * history of migraines with aura * history of liver disease * family or personal history of blood clots (thromboembolism) * mental disabilities * desire to become pregnant in the next six months

Keywords: birth control pills oral contraceptives brand name generic side effects oral contraceptive side effects dysfunctional uterine bleeding pre-menstrual symptoms
laparoscopic staging for locally advanced gastric cancer in chinese patients

Conditions: Gastric Cancer; Peritoneal Metastases

Summary: rationale: laparoscopic staging may help doctors plan more effective treatment for gastric cancer, yet the efficiency have not been fully investigated in chinese people. purpose: study the effectiveness of laparoscopic staging in patients with pre-diagnosed as locally advanced gastric cancer.

objectives: i. determine the feasibility of laparoscopic staging of patients with pre-diagnosed as locally advanced gastric cancer. ii. assess the adverse effects associated with this technique. outline: surgery. laparoscopy with cytologic examination. projected accrual: up to 450 patients will be accrued over approximately 2 years.

Eligibility criteria:
inclusion criteria: * sign written informed consent form * age ≥ 18 years * pathologically confirmed gastric or gej adenocarcinoma * disease at clinical stage of locally advanced gastric cancer by ct/eus(ct2+nanym0) * no prior antitumor treatment is allowed, including chemotherapy, radiotherapy, immune therapy or target therapy * adequate organ function as defined below: hematologic anc ≥ 1.5\*109/l hemoglobin ≥ 9 g/dl platelets ≥ 100\*109/l hepatic albumin ≥ 30g/l serum bilirubin ≤ 1.5×uln ast and alt ≤ 2.5×uln alp ≤ 2.5×uln tbil ≤ 1.5×uln renal serum creatinine \< 1.5 uln * kps ≥ 70 * adequate lung and heart function * negative serum or urine pregnant test within 7 days prior to randomization for child-bearing age women * sexually active males or females willing to practice contraception during the study until 30 days after end of study. exclusion criteria: * refuse to provide blood/tissue sample； * with distant metastasis diagnosed by ct/eus； * sexually active males or females refuse to practice contraception during the study until 30 days after end of study. * history of organ transplantation（including autologous bone marrow transplantation and peripheral stem cell transplantation）； * prior long term steroid therapy (excluding short term steroid treatment which is completed prior to \> 2 weeks of study enrollment)； * patients with central nervous system(cns) disorder or peripheral nervous system disorder or psychiatric disease； * concurrent severe infection； * concurrent disease or condition that would make the subject inappropriate for study participation or any serious medical disorder that would interfere with the subject's safety (including current active hepatic, biliary, renal, respiratory disease, uncontrolled diabetes hypertension et al)； * history of other malignancy. however, subjects who have been disease-free for 5 years, or subjects with a history of completely resected non-melanoma skin cancer or successfully treated in situ carcinoma, are eligible； * known history of uncontrolled or symptomatic angina, uncontrolled arrhythmias and hypertension, or congestive heart failure, or cardiac infarction within 6 months prior to study enrollment, or cardiac insufficiency； * person with no capacity (legally) or inappropriate to continue study treatment for ethics/medical reasons.

Keywords: gastric cancer laparoscopic staging cytology peritoneal metastases
effect of ankle position and pelvic floor muscle force with relaxation of pelvic floor muscles syndrome

Conditions: Pelvic Floor Muscle Syndrome

Summary: strengthening exercises of pelvic floor muscles (pfm) is the first line treatment for female pelvic floor dysfunction. actually the best position to facilitate pfm force is controversial in different studies. the aim of this study is to assess the effect of ankle positions on pelvic ﬂoor muscle force during pfm exercises. this clinical trial study was carried out on 58 women aged 25-55 years with relaxation of pelvic floor muscles who referred to women's clinic of educational hospitals of mashhad university of medical sciences in 1389. after clinical examination and confirmation of pelvic floor muscle relaxation, women were randomize divided into 3 groups, doing strengthening exercises of pfm in standing position with passive ankle dorsi ﬂexion (on wooden surface with 15 degree angle)(n=20), active ankle plantar ﬂexion with arm up (standing on toe)(n=20) and horizontal standing position (n=19) for 8 weeks. pfm exercises were instructed to women by using a pamphlet and face to face education. they were followed up every two week by telephone call and were asked to refer to women's clinic after 4 \& 8 weeks. pelvic floor muscles strength was assessed with brink score before and after intervention. data analyzed by using analytic-descriptive statistics.


Eligibility criteria:
inclusion criteria: * age 25-55 * bma 20-30 * women with relaxation of pelvic floor muscles syndrome in ph.ex and inspection exclusion criteria: * severe deformity in knee joint and ankle * regular exercise or yoga * severe or moderate vaginal atrophy

Keywords: ankle positions pelvic floor muscles strength relaxation of pelvic floor muscles syndrome doing strengthening exercises of pelvic floor muscles
influence of extracorporeal circulation on the development of osa (obstructive sleep apnea)

Conditions: Coronary Artery Disease

Summary: * 1. coronary artery bypass grafting (cabg) could be performed with or without extracorporeal circulation (ecc). * 2. osa (obstructive sleep apnea) could be influenced by in intravenous perfusion. * 3. ecc could influence the amount of intravenous perfusion administered to the patient. the aim of this study was to examine the influence of ecc on the development of osa.

* 1. coronary artery bypass grafting (cabg) could be performed with or without extracorporeal circulation (ecc). * 2. osa (obstructive sleep apnea) could be influenced by in intravenous perfusion. * 3. ecc could influence the amount of intravenous perfusion administered to the patient. the aim of this study was to examine the influence of ecc on the development of osa. the ahi (apnea hypopnea index) will be used to assess this potential influence.

Eligibility criteria:
inclusion criteria: * all of the patients scheduled for an elective cabg exclusion criteria: * patient's refusal

Keywords: coronary artery disease obstructive sleep apnea
vein of galen aneurysm

Conditions: Vein of Galen Malformation

Summary: 1. foundations of the clinical research project: vein of galen vascular malformations are a group of rare cerebral vascular malformations with complex anatomy and severe clinical consequences. the pathology consists of direct communications between small intracerebral arteries and veins without the presence of capillaries. the result is a vascular malformation with low resistance and high flow, a lesion that will evolve during fetal development into aneurysmal dilatation. these lesions evolve towards rupture, but due to the high flow rate through these malformations, children very quickly develop cardiac decompensation (high-output failure). treatment must be rapid, often on the first day of life. the technique currently used is iterative embolization. general anaesthesia is required for this procedure. however, neonatal anesthesia in children with cardiac decompensation and pulmonary hypertension poses major challenges for the anesthesia team. a high percentage of these patients require a short stabilization period with management of cardiac decompensation and pulmonary hypertension, most often by continuous milrinone infusion. hôpital erasme is a reference center for the management of vein of galen malformations. in this work, we propose to analyze all cases of children with veins of galen malformations managed by the interventional neuroradiology department. 2. objectives of the clinical research project: 2.1 main objective: description of cerebral lesions as described by angiography. details of anesthetic management with all anesthetic drugs, details of cardiac management. details of ventilatory management, intubation duration required. description of embolization outcome. description of the neurological and cardiac outcome. 2.2 secondary objectives: possibly, depending on the number of patients, attempt to identify factors predictive of poor outcome. 3. methodology of the clinical research project: we will carry out a retrospective analysis of the records of all patients who have been managed at erasme for vein of galen-type malformation. activity began ± in 2011, and we will produce a listing of all patients from 2010 to august 2024. from this listing, obtained by the radiology department, we will collect data from the patients computer files. 4. design of the clinical research project: this is a retrospective study based on file analysis. 5. participants: all patients treated at erasme for a vein of galen malformation. we will check the file to ensure that the parents have not expressed any opposition to the use of the patient medical data.


Eligibility criteria:
inclusion criteria: - all patients treated at erasme for a vein of galen malformation exclusion criteria: - opposition of parents to the use of medical data

Keywords: vein of galen aneurysm neuroradiological embolization
pulmonary rehabilitation program in copd patient

Conditions: Chronic Obstructive Pulmonary Disease

Summary: this study was designed in order to evaluate the compliance of a pulmonary rehabilitation program using a wearable device and the application effect of the program according to the characteristics of each patient, in copd patients.

chronic obstructive pulmonary disease (copd) is characterized by persistent respiratory symptoms and airflow limitation. symptoms of copd often restricts exercise capacity and activities of daily life of patients. accordingly, patients with symptomatic copd have reduced health-related quality of life, which leads to substantial socioeconomic burden. in order to overcome the limitation associated with copd pharmacotherapy, the need for a combination of nonpharmacologic therapies, including pulmonary rehabilitation has been suggested constantly. pulmonary rehabilitation is a method of relieving respiratory distress symptoms through exhalation and inspiratory training, improving exercise ability and contributes in improving lung function and overall quality of life. nevertheless, compliance of pulmonary rehabilitation in daily life is low in most copd patients. thus, we applied wearable device to detect and evaluate application, compliance and effectiveness pulmonary rehabilitation program in copd patients, according to the patients' characteristics. moreover, we sought to use the results of this study as a basic data to establish a strategy for a customized education program for each patient that can be applied to non-face-to-face digital therapeutics in the future.

Eligibility criteria:
inclusion criteria: * copd patients 18 years of age or older * ecog ps (eastern cooperative oncology group performance status) \<2 * smart phone user * those who understand the contents of the questionnaire and agree to the research exclusion criteria: * patients with history of lung cancer surgery * patients with bronchiectasis, severe tuberculosis destroyed lung, active pulmonary tuberculosis, non-tuberculous mycobacterial lung disease (ntm), and idiopathic interstitial pneumonia

Keywords: pulmonary rehabilitation tele-rehabilitation
diastolic deceleration area in early-onset fgr

Conditions: Hypoxia; Anemia

Summary: dda is a new doppler parameter aiming to assess fetal well-being in-utero. early-onset sgr is a specific subgroup of fetuses where the clinical application of this doppler modality could play an important role in the detection of hypoxia, anemia, and brain-sparing.


Eligibility criteria:
inclusion criteria: * absence of fetal abnormalities and/or genetic conditions; * single pregnancy; * fetal growth restriction (fgr) \< 10%, according to the intergrowth 21st nomograms, appearing before 32nd week of gestation exclusion criteria: * documented fetal abnormalities and/or genetic conditions in the course of the pregnancy; * multiple pregnancy; * absence of fetal growth restriction (fgr) \< 10%, according to the intergrowth 21st nomograms before 32nd week of gestation
phase ii trial of zanubrutinib, obinutuzumab, bendamustine (zgb) as first-line therapy for chronic lymphocytic leukemia: a single-center study

Conditions: Chronic Lymphocytic Leukemia

Summary: this is a single arm, open label, national multicenter clinical study included patients with chronic lymphocytic leukemia (cll). the treatment combines three medications: zanubrutinib , obinutuzumab and bendamustine . together, these drugs aim to achieve deep remission (no detectable cancer cells) and allow a shorter treatment duration compared to lifelong therapies.


Eligibility criteria:
inclusion criteria: 1. demographics: age ≥18 years, regardless of gender. 2. diagnosis: confirmed diagnosis of untreated chronic lymphocytic leukemia (cll) per iwcll 2018 criteria. 3. treatment naivety: * no prior systemic therapy for cll, including: * chop/cop-based chemotherapy. * regimens containing fludarabine or bendamustine. * anti-cd20 monoclonal antibodies (e.g., rituximab) or btk inhibitors (e.g., ibrutinib). * chlorambucil or cyclophosphamide (\>3 weeks of use). * interferon therapy (\>6 months of use). 4. treatment indications: * must meet ≥1 of the following (iwcll 2018 criteria): * hemoglobin \<100 g/l (non-hemolytic). * platelets \<100×10⁹/l with progressive decline. * lymphadenopathy (longest diameter \>10 cm) or massive splenomegaly (\>6 cm below costal margin). * constitutional symptoms: unexplained fever (\>38°c ×2 weeks), night sweats, or \>10% weight loss in 6 months. * rapid disease progression (lymphocyte doubling time \<6 months, 50% lymph node growth in 2 months, or rapid cytopenia). 5. performance status: ecog performance status ≤2. 6. organ function (within 7 days before enrollment): hematologic: * anc ≥1.0×10⁹/l (without growth factor support). * platelets ≥50×10⁹/l (without transfusion). * hepatic: ast/alt ≤2.5×uln; total bilirubin ≤1.5×uln. * renal: estimated crcl ≥30 ml/min (cockcroft-gault formula). 7. consent: signed informed consent. exclusion criteria: 1. malignancy: history of active malignancy (excluding cll) within the past year, including cns lymphoma. 2. disease transformation: richter transformation or prolymphocytic leukemia (pll). 3. autoimmune cytopenias: active autoimmune hemolysis or thrombocytopenia requiring corticosteroids. 4. organ dysfunction: alt/ast \>3×uln; total bilirubin \>2×uln; creatinine \>1.5×uln. 5. comorbidities: uncontrolled diabetes, cardiac/pulmonary disease, or conditions deemed by investigators to affect study safety. 6. infections: active systemic infection requiring iv antibiotics. 7. bleeding risks: history of life-threatening hemorrhage or need for high-dose anticoagulation. 8. recent surgery: major surgery within 30 days. 9. reproductive status: pregnancy, lactation, or unwillingness to use contraception. 10. drug tolerance: hypersensitivity to any study drug components. 11. viral infections: active hbv (hbsag+ or hbv-dna+) or hcv. 12. other: investigator-determined ineligibility (e.g., poor compliance, psychiatric disorders).
transcutaneous electrical acustimulation in the treatment of mild to moderate ulcerative colitis

Conditions: Ulcerative Colitis

Summary: the aim of this study was to evaluate the efficacy and safety of transcutaneous electrical acustimulation in patients with mild to moderate ulcerative colitis.


Eligibility criteria:
inclusion criteria: 1. age ≥18 years 2. ulcerative colitis diagnosed for at least 3 mouths. 3. mayo score 4-10, mayo endoscopic score 2-3 points 4. resistant to at least one type of medical treatments exclusion criteria: 1. treatment-naive ulcerative colitis (no previous treatment) 2. acute severe ulcerative colitis 3. previous surgical treatment or severe colitis at imminent risk of surgery infective colitis 4. other systemic diseases 5. pregnancy and lactation 6. allergic to the electrode patch
a study of hd-tdcs and cognitive training to improve cognitive function in mci

Conditions: Mild Cognitive Impairment; Memory Disorders; Memory Loss

Summary: the primary objective of this project is to assess the feasibility of multi-field, extended hd-tdcs (mfe-hd-tdcs) with simultaneous computerized ct as a viable intervention to improve cognitive function in patients with mci. this double-blinded, randomized pilot clinical trial of repetitive daily hd-tdcs/sham hd-tdcs, administered in combination with ct to subjects with mci in 3 monthly blocks of 5 daily sessions for a total of 15 sessions will enroll 8 participants.


Eligibility criteria:
inclusion criteria: 1. age ≥50-90 years 2. right handed 3. willing and able to undergo all procedures 4. retains decisional capacity at initial visit 5. meets criteria for mci, amnestic type (petersen, 2004). exclusion criteria: 1. left handed patients 2. significant kidney injury requiring hemodialysis 3. automatic internal cardiac defibrillator (aicd) or pacemaker 4. significant congestive heart failure 5. history of clinically significant ischemic or hemorrhagic stroke, or lacune or infarct considered by radiologist likely to cause or contribute significantly to cognitive symptoms 6. history of thalamic lacunar stroke 7. modified hachinski ischemia score \>4 points 8. history of seizure disorder requiring medication 9. history of brain surgery (for seizure disorder, aneurysms, or benign/malignant tumor) 10. history of hiv/aids 11. severe untreated obstructive sleep apnea 12. greater than three servings alcohol daily or illicit drug use 13. major neurologic disorders other than dementia (e.g., ms, als) 14. schizophrenia, bipolar disorder, other serious mental illnesses 15. other significant medical conditions at investigators' discretion 16. pregnancy